A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, sequential, international, multicentric, 2-arm,
non-comparative, open-label, 2-stage clinical study to determine disease response rates to
Velcade™ therapy in subjects who have relapsed or refractory follicular B-cell lymphoma.
Qualitative comparisons of the 2 treatment arms based on safety, efficacy and dosing
convenience will be made in order to recommend a dose schedule for further clinical study.